Ebola

The portable analyzer runs an RT-qPCR-based Ebola assay and takes about 75 minutes to detect the presence of the virus from whole blood.

BioInnovation Solutions, formerly Pathogenica, and Enzymatics are developing a rapid Ebola diagnostic and have validated it on patient samples in Nigeria.

The tests use the company's Nanotrap reagents, hydrogel nanoparticles functionalized with internal affinity baits to enrich target analytes for downstream analysis.

Qiagen announced today it will offer global distribution of the Altona Diagnostics RealStar Ebolavirus RT-PCR Kit 1.0.

The firms intend to seek Emergency Use Authorization from the US Food and Drug Administration once the Ebola assay is developed. 

Photo of Nathan Ledeboer

Point-of-care testing, automation, and panelization of nucleic acid amplification testing are the future of the clinical lab ― and will likely change how labs and clinicians relate.

The method may be deployed as part of the Broad's collaboration with Illumina and USAID to study Ebola in some West African countries hit by the outbreak.

The Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation awarded the grant to Cepheid to develop the test.

NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals may not be able to meet its year-end goal of providing US regulators with the data required to lift a hold on a Phase I trial of its investigational Ebola therapy TKM-Ebola, company officials disclosed last week.

Pages

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.